Public release date: 29-Nov-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, November 29, 2012Asian-American children have been at low risk for being overweight or obese compared to other racial and ethnic groups in the U.S., but that may be changing. Yet as rates of overweight and obesity rise, the risk appears to vary depending on the Asian country of origin, according to an article in Childhood Obesity, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Childhood Obesity website at http://www.liebertpub.com/chi.

In the article "Prevalence of Obesity among Young Asian-American Children," weight measurements from Asian-American 4-year-olds showed that 26% were overweight or obese and 13% were obese. The study included the following Asian ethnic categories: Chinese, Japanese, Filipino, Asian Indian, Korean, Vietnamese, and Other Asian/Pacific Islander.

When the children were divided into groups based on the mother's ethnicity, the study authors, Anjali Jain, MD et al. from The Lewin Group (Falls Church, VA), Children's National Medical Center, George Washington University School of Health and Health Sciences, Georgetown University (Washington, DC), and Medical College of Virginia (Richmond), found that while Chinese-American children were at lower risk of overweight or obesity (23.5%) than Whites (36%), Asian-Indian American children had the lowest rates (15.6%) and were the most likely to be underweight. In contrast, Vietnamese-American children had the highest rate of overweight or obesity (34.7%).

"To some extent, this important article highlights variable vulnerability to childhood obesity, based on ethnicity and culture. But what may be most important is the message that groups we long thought of as relatively immune no longer are," says David L. Katz, MD, MPH, Editor-in-Chief of Childhood Obesity and Director of Yale University's Prevention Research Center. "The obesigenic forces that prevail in the developed and developing countries of the world appear to trump genes and ethnicity, and appear to be stronger than traditional cultural practices. We are all in this together, and thus all have common cause that transcends borders and cultural practices to devise the array of defenses we and our children need."

###

About the Journal Childhood Obesity is a bimonthly journal, published in print and online, and the journal of record for all aspects of communication on the broad spectrum of issues and strategies related to weight management and obesity prevention in children and adolescents. The Journal includes peer-reviewed articles documenting cutting-edge research and clinical studies, opinion pieces and roundtable discussions, profiles of successful programs and interventions, and updates on task force recommendations, global initiatives, and policy platforms. It reports on news and developments in science and medicine, features programs and initiatives developed in the public and private sector, and includes a Literature Watch. Tables of content and a sample issue may be viewed on the Childhood Obesity website at http://www.liebertpub.com/chi.

About the Publisher Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative medical and biomedical peer-reviewed journals, including Metabolic Syndrome and Related Disorders, Population Health Management, Diabetes Technology & Therapeutics, and Journal of Women's Health. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, newsmagazines, and books is available on the Mary Ann Liebert, Inc., publishers website at http://www.liebertpub.com.

Mary Ann Liebert, Inc. 140 Huguenot Street, New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone (914) 740-2100 (800) M-LIEBERT Fax (914) 740-2101

Read the original post:
Which group of Asian-American children is at highest risk for obesity?

Recommendation and review posted by Bethany Smith

Public release date: 29-Nov-2012 [ | E-mail | Share ]

Contact: Christopher Rucas christopher.rucas@nyumc.org 212-404-3525 NYU Langone Medical Center / New York University School of Medicine

Scientists at NYU Langone Medical Center have identified two genes involved in establishing the neuronal circuits required for breathing. They report their findings in a study published in the December issue of Nature Neuroscience. The discovery, featured on the journal's cover, could help advance treatments for spinal cord injuries and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), which gradually kill neurons that control the movement of muscles needed to breathe, move, and eat.

The study identifies a molecular code that distinguishes a group of muscle-controlling nerve cells collectively known as the phrenic motor column (PMC). These cells lie about halfway up the back of the neck, just above the fourth cervical vertebra, and are "probably the most important motor neurons in your body," says Jeremy Dasen, PhD, assistant professor of physiology and neuroscience and a member of the Howard Hughes Medical Institute, who led the three-year study with Polyxeni Philippidou, PhD, a postdoctoral fellow.

Harming the part of the spinal cord where the PMC resides can instantly shut down breathing. But relatively little is known about what distinguishes PMC neurons from neighboring neurons, and how PMC neurons develop and wire themselves to the diaphragm in the fetus.

The PMC cells relay a constant flow of electrochemical signals down their bundled axons and onto the diaphragm muscles, allowing the lungs to expand and relax in the natural rhythm of breathing. "We now have a set of molecular markers that distinguish those cells from other populations of motor neurons, so that we can study them in detail and look for ways to selectively enhance their survival," Dr. Dasen says. Degeneration of PMC neurons is the primary cause of death in patients with ALS and spinal cord injuries.

To find out what distinguishes PMC neurons from their spinal neighbors in mice, Dr. Philippidou injected a retrograde fluorescent tracer into the phrenic nerve, which wires the PMC to the diaphragm, and then looked for the spinal neurons that lit up as the tracer worked its way back to the PMC. He used transgenic mice that express green fluorescent protein (GFP) in motor neurons and their axons in order to see the phrenic nerve. After noting the characteristic gene expression pattern of these PMC neurons, Dr. Philippidou began to determine their specific roles. Ultimately, a complicated strain of transgenic mice, based partly on mice supplied by collaborator Lucie Jeannotte, PhD, at the University of Laval in Quebec, revealed two genes, Hoxa5 and Hoxc5, as the prime controllers of proper PMC development. Hox genes (39 are expressed in humans) are well known as master gene regulators of animal development.

When Hoxa5 and Hoxc5 are silenced in embryonic motor neurons in mice, the scientists reported, the PMC fails to form its usual, tightly columnar organization and doesn't connect correctly to the diaphragm, leaving a newborn animal unable to breathe. "Even if you delete these genes late in fetal development, the PMC neuron population drops and the phrenic nerve doesn't form enough branches on diaphragm muscles," Dr. Dasen says.

Dr. Dasen plans to use the findings to help understand the wider circuitry of breathingincluding rhythm-generating neurons in the brain stem, which are in turn responsive to carbon dioxide levels, stress, and other environmental factors. "Now that we know something about PMC cells, we can work our way through the broader circuit, to try to figure out how all those connections are established," he says.

"Once we understand how the respiratory network is wired we can begin to develop novel treatment options for breathing disorders such as sleep apneas," adds Dr. Philippidou.

See the original post here:
Scientists describe the genetic signature of a vital set of neurons

Recommendation and review posted by Bethany Smith

The Hidden Source Episode 32 -CASPER IS MY FRIEND-
Myself ThatOneRebel playing some The Hidden Source! Nobody can see The Hidden only trained eyes can see him well! WATCH AS I MURDER EVERYONE AS THE HIDDEN MAHAAAHAHAHA The objective of The Hidden Source is that the humans aka IRIS must eliminate The Hidden to win vice versa for the Hidden but as the title says he is invisible and only is equipped with a knife capable of a one hit kill depending on server and only three grenades. The hidden has many abilities like taunting, super strength to ram objects into IRIS soldiers or be able to leap super high and hang on buildings. Lastly The Hidden can heal himself by eating bodies but only if they are stabbed to death not PIGSTICKED! (which is the one hit kill move) The IRIS are equipped with four weapons ranging from shotgun to rifle to SMG and a few options of equipment like senors to laser optics on your gun. Game is The Hidden Source which requires Half life 2 engine meaning you have to have Half Life 2 purchased already or another source game to run with STORYLINE In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid ...From:ThatOneRebel55Views:4 1ratingsTime:12:50More inGaming

Link:
The Hidden Source Episode 32 -CASPER IS MY FRIEND- - Video

Recommendation and review posted by Bethany Smith

Welcome to the Human and Molecular Genetics Center at MCW
Howard Jacob, Ph.D., director and founder of MCW #39;s personalized medicine program at the Human and Molecular Genetics Center, explains personalized medicine and how it will change the face of health care.From:Maureen MackViews:0 0ratingsTime:03:16More inScience Technology

Read more from the original source:
Welcome to the Human and Molecular Genetics Center at MCW - Video

Recommendation and review posted by Bethany Smith

Cannabis Cup 2012 Delta 9 Genetics - Winston Party
We talk with Ed from Delta 9 Genetics and smoke some Rock Star from Bonguru Seeds.From:urbanremoViews:1179 42ratingsTime:05:47More inNonprofits Activism

View post:
Cannabis Cup 2012 Delta 9 Genetics - Winston Party - Video

Recommendation and review posted by Bethany Smith

What is the difference between a talent and a spiritual gift
http://www.missionarymandate.org What is the difference between a talent and a spiritual gift? A summary of the transcript is found below First, let #39;s look at the similarities between a talent and a spiritual gift. Both are from God. (God makes his son to shine on both the good and the bad) Both are perfected with use. Both are given for the benefit of others. Can have more than one of each type. Spiritual gifts listed in 1 Cor. 12; Rom 12; Eph. 4; 1 Peter 4 Differences between talents and spiritual gifts. 1) A talent is the result of a person #39;s genetics and/or training. A spiritual gift is a manifestation of the power of the Holy Spirit. 2) Talents are given by God to anyone, Christian or non-Christian. Spiritual gifts are only possessed given to Christians. 3) Both talents and spiritual gifts are given to be used for God #39;s glory and to serve others. However, spiritual gifts are specifically given to build the church. 4) Talents are given at birth. Spiritual gifts are given at the new birth, when a person becomes a Christian.From:ourshapingdestinyViews:2 0ratingsTime:09:14More inFilm Animation

Read this article:
What is the difference between a talent and a spiritual gift - Video

Recommendation and review posted by Bethany Smith

Dentist Edmonton - For Your Bright Smile! Call 780-666-3284
Dentist Edmonton - For Your Bright Smile! Call Your Edmonton Dentist 780-666-3284 Today! There is a Chinese proverb that goes something like, "smile will gain you 10 years of life." These words were written several hundred years ago, but today they are more real than ever: the relationship between oral health and overall health are seen on a daily basis, and this result is amazing! By brushing and flossing regularly, you can avoid a heart attack. We are not be there yet, but there is a growing link between periodontal disease and heart disease, diabetes and pregnancy complications: While the investigation continues, we learn that a healthy smile can really add 10 years to your life. At the heart of this research is a substance, which scientists call biofilms. If the word "biofilm" provides images of horror and Sci-Fi, you #39;re not far away. In real life, biofilm is important. It forms a colorless film on teeth, and this substance accumulates in time , and can lead to life-threatening health problems. Gum disease, also called periodontal disease, includes different stages of disease, including periodontal infection. periodontal literally means "around the tooth." The interesting thing is as the disease progresses, it may be under and affect the tooth or teeth. The initial phase of periodntal disease, which occurs when plaque begins inflamming the gums, causing them to become red, swollen and bleed easily. Usually, there is no discomfort at this stage. during a visit to a ...From:DentistEdmontonViews:2 0ratingsTime:01:02More inPeople Blogs

Follow this link:
Dentist Edmonton - For Your Bright Smile! Call 780-666-3284 - Video

Recommendation and review posted by Bethany Smith

30 days of Movember in 30 seconds
Thanks to Movember for giving me the chance to try to grow a Mo...and thanks to genetics for proving to me that I can #39;t. Feel free to send pity donations to au.movember.comFrom:2degreesofseparationViews:0 0ratingsTime:00:32More inHowto Style

Original post:
30 days of Movember in 30 seconds - Video

Recommendation and review posted by Bethany Smith

Cyprus-based molecular diagnostics startup NIPD Genetics has taken another key step toward commercializing its flagship assay, a noninvasive prenatal diagnostic test for Down syndrome.

The company published the findings of its most recent validation study for the test, which combines methylated DNA immunoprecipitation with quantitative real-time PCR, in the October issue of the journal Prenatal Diagnosis, reporting a sensitivity of 100 percent and specificity of 99.2 percent.

NIPD Genetics is now putting together an even larger validation study of 1,000 pregnant women from various European countries with an eye toward completing the trial and offering its assay as a genetic testing service in Europe next year, company officials said this week.

To that end, NIPD Genetics said it is also looking to raise up to 4 million (about $5.2 million) in a second round of equity financing.

NIPD Genetics, a spinout of the Cyprus Institute of Neurology and Genetics, published the first peer-reviewed study of its test in Nature Genetics in March 2011 (PCR Insider, 3/10/2011).

The test involves collecting 10 mL of peripheral blood from a pregnant woman, then isolating the DNA. This is followed by methylated DNA immunoprecipitation, or MeDiP, which uses an antibody specific for 5-methylcytidine to capture methylated sites and enrich for DNA regions that are specifically hypermethylated in the fetal DNA and hypomethylated in the maternal DNA.

After methylation enrichment of the fetal DNA in maternal circulation, the researchers use qRT-PCR to quantify the amount of fetal DNA in the test sample. By comparing the amount of fetal DNA present in an unknown sample to that of a control sample from a pregnant woman known to carry a normal fetus, the technique can quantify the extra copy of chromosome 21 and distinguish Down syndrome pregnancies from normal pregnancies.

In last year's Nature Genetics paper, the company used the method to correctly diagnose 14 cases of Down syndrome and 26 normal cases from maternal peripheral blood samples, achieving 100 percent sensitivity and specificity.

That test began with a group of 12 differentially methylated regions, or DMRs, that the group had identified, eventually yielding a diagnostic formula for eight of those 12 regions.

However, since that time the company dug further into the literature to discover that some of these DMRs are located on high copy number regions of the chromosome, which could have caused some difficulties in classification, Elisavet Papageorgiou, NIPD Genetics' CSO, told PCR Insider this week.

Follow this link:
Cyprus' NIPD Genetics Validates Updated Trisomy 21 Assay; Eyes 2013 Launch for Testing Services

Recommendation and review posted by Bethany Smith

Some Horry County Schools students got a first-hand look at how a state-of-the-art genetics laboratory operates, courtesy of a genetics research facility that makes its home in South Carolina but treats people from all over the world.

The Gene Machine, a lab housed in a 41-foot custom bus, is the educational arm of the Greenwood Genetic Center, a nonprofit institute that provides clinical genetic services, diagnostic laboratory testing and research in medical genetics.

The bus made stops this week at the Academy for Technology and Academics, Myrtle Beach High School and Aynor High School with a mission to improve genetic literacy among high schools students using hands-on activities and to introduce them to careers in the fields of genetics and biotechnology.

Its awesome my students just love it, said Teresa Nirenstein, health science and pre-med instructor at ATA, as 25 of her pre-med juniors climbed into the mobile lab Tuesday. Its an impressive display of practical technology on wheels.

The students sat at tables outfitted with various tools of the genetics trade so they could learn how to test faux samples for the sickle cell anemia trait. Genetics instructors Jackie Cascio and Katie Henderson were on hand to guide the exercise step by step, answer questions and hopefully get them interested in science, Henderson said.

Students donned aprons and gloves before checking the tips on their micropipettes, instruments used to measure and dispense microscopic samples. Keeping their instruments vertical, they carefully loaded controlled samples into a gel substance.

Ive never known anything like this, so Im learning a lot, said Chelsea Billingsley, who is aiming to become a psychiatrist.

The gel was then loaded into an electrophoresis box that was put into a buffer liquid mostly made of water. Cascio sent an electric current, 275 volts, through the samples, which pushed them through the gel. The samples could then be identified and compared based on how far they traveled.

Its like jumping your car battery, Cascio said.

Robert Philius said he was already familiar with some things in the lab and was enjoying the exercise.

Read more:
Education notebook | Mobile genetics lab brings science to students

Recommendation and review posted by Bethany Smith

Genetic sequences of drug-resistant bacteria have helped scientists better understand how these dastardly infections evolve--and elude treatment. But these superbugs are still claiming lives of many who acquire them in hospitals, clinics and nursing homes. And recent outbreaks of these hard-to-treat infections can spread easily in healthcare settings. Researchers might soon be able to track outbreaks in real time, thanks to advances in sequencing technology. So say Mark Walker and Scott Beaston, both of the School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research Center at the University of Queensland in Australia, in an essay published online November 29 in Science. "Genomic sequencing can provide information that gives facilities a head start in implementing preventive measures," they wrote. Current preventive measures, such as increasing healthcare worker hand washing and isolating infected patients, have helped to reduce the spread of many healthcare-acquired infections. But these preventable infections still kill some 100,000 patients in the U.S. each year. Walker and Beatson think genomics has the capacity to "revolutionize current practice in clinical microbiology," which currently relies primarily on culturing pathogens in the lab to study strain differences--a time-consuming process. Some promising examples have already emerged. A 2011 outbreak of Klebsiella pneumoniae (KPC), which is resistant to most known antibiotics, at the National Institutes of Health's Clinical Center killed 11 patients and infected many others. Genetic sequencing of samples from patients and from healthcare workers allowed epidemiologists to track the outbreak to a single patient and to trace its spread. The KPC analysis even pinpointed a transmission event in which a contaminated ventilator was used on a new patient. This level of detail points to the ability of "genome sequencing-based epidemiology to influence hospital management practices," the researchers noted. These discoveries, however, were made after the outbreak was underway. "In a real-time clinical situation, this information would enable further targeted testing of other patients or healthcare professionals to identify intermediate carriers," Walker and Beatson wrote. Moving closer to real-time tracking, researchers sequenced and analyzed strains from a 2011 outbreak of methicillin-resistant Staphylococcus aureus (MRSA) in a neonatal intensive care unit in Cambridge, in the U.K., while the outbreak was still occurring. A local clinical microbiologist wondered whether infants who had contracted the superbug had strains related to those currently circulating in other clinics and hospital areas. A team sequenced samples and found that not all of the strains were related, but that there was indeed a clear outbreak cluster in the neonatal unit. The microbiologists were then able to trace potential means of spread and thereby reduce the risk of further spread. The genetic sequencing, completed on a bench-top sequencer, also provided information about the strain's virulence and nature of its antibiotic resistance. These instances "point to a future in which direct sequencing of clinical samples allows same-day diagnosis, antibiotic resistance gene profiling and virulence gene detection," Walker and Beatson noted. Such sequencing and analysis is still too expensive and labor-intensive for most health care institutions. But as technologies improve, putting the tools within reach, clinical microbiologists might be soon able to stop these superbug outbreaks before they start.

Follow Scientific American on Twitter @SciAm and @SciamBlogs. Visit ScientificAmerican.com for the latest in science, health and technology news. 2012 ScientificAmerican.com. All rights reserved.

See more here:
Real-Time Genetics Could Squash "Superbug" Outbreaks before They Spread

Recommendation and review posted by Bethany Smith

LOS ANGELES, Nov. 29, 2012 /PRNewswire/ -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that Thomas A. Bologna, Chairman and CEO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York, NY.

Mr. Bologna's presentation is scheduled to begin at 2:30 p.m. EST on Tuesday, December 4, 2012. Interested investors can access a live webcast of the presentation by going to the Investor Relations tab on the Response Genetics website: http://www.responsegenetics.com.

About Response Genetics, Inc. Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer.The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens.The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry.The Company's headquarters is located in Los Angeles, California.For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDXproducts, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Company Contact:

Peter Rahmer

See the article here:
Response Genetics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Nov 29, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO and president of Atossa Genetics, Inc., will present at the 5th Annual LD Micro Conference on Wednesday, December 5, 2012, at 10:00 AM Pacific Time, at the Luxe Sunset Bel Air Hotel in Los Angeles, California.

Dr. Quay's presentation will focus on the Company's novel approaches to breast cancer risk assessment and prevention, 2013 growth initiatives for its first year as a public company, and its unique investment thesis.

A link to the live audio webcast with slides of the presentation can be accessed on Atossa's website. After clicking on the webcast link, visitors will be directed to the proper conference's registration page. After completing the required fields and clicking "Register," visitors will then be brought to the dedicated webcast page. A replay of the webcast will be available for 90 days after the presentation and can be accessed at the same web address.

The LD Micro Conference is a two-day conference organized by LD Micro, a by-invitation only newsletter firm that provides micro-cap research for its clients. The LD Micro Conference focuses on undervalued micro-cap companies in a broad range of industries. A record 580 investors attended the 2011 event. Investors interested in attending the conference should call 408-457-1042 or e-mail Chris@ldmicro.com, or visit the conference website.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Read more from the original source:
Atossa Genetics, Inc. to Present at the 5th Annual LD Micro Conference

Recommendation and review posted by Bethany Smith

Metal Gear Solid: The Twin Snakes Game Movie
http://www.gamematics.net During a training mission on Shadow Moses, a nuclear weapons training facility on a remote island off the coast of Alaska, the Special Forces unit FOXHOUND rebelled against the United States government, under the command of Liquid Snake. Their target was the advanced weapon system Metal Gear REX, a gigantic robotic weapons platform able to independently launch a nuclear warhead at any target on the face of the planet. Their demand was the body of the greatest soldier who ever lived, Big Boss, which, through gene therapy, they could use to create an army of ultimate soldiers. With the safety of the entire world at stake, Colonel Roy Campbell, the former commander of FOXHOUND, summoned Solid Snake out of retirement for one last solo covert operation. Gameplay MrPlentl Developer: Silicon Knights Konami Publisher: KonamiFrom:lapman17Views:9 1ratingsTime:03:43:40More inGaming

Continue reading here:
Metal Gear Solid: The Twin Snakes Game Movie - Video

Recommendation and review posted by Bethany Smith

"Spiking Levels" Found At Paulsboro Crash Site Force Evacuation "Spiking Levels" Found At Paulsboro Crash Site Force Evacuation

Updated: Friday, November 30 2012 11:49 PM EST2012-12-01 04:49:14 GMT

Concerns about health safety are growing tonight. About 500 people have been told to evacuate. Officials are concerned with increased levels of a hazardous chemical.

Concerns about health safety are growing tonight. About 500 people have been told to evacuate. Officials are concerned with increased levels of a hazardous chemical.

Updated: Friday, November 30 2012 11:04 PM EST2012-12-01 04:04:06 GMT

Newark Police are investigating a home invasion where three men forced their way into a home and ordered three people to sit on the coach while they ransacked the apartment.

Newark Police are investigating a home invasion where three men forced their way into a home and ordered three people to sit on the coach while they ransacked the apartment.

Updated: Friday, November 30 2012 6:31 PM EST2012-11-30 23:31:59 GMT

In a statement issued Friday, Eagles quarterback Michael Vick says he's focused on rejoining the team on the field.

In a statement issued Friday, Eagles quarterback Michael Vick says he's focused on rejoining the team on the field.

View post:
2 Kids Suffering From Rare Disease Admitted Into Gene Therapy Study

Recommendation and review posted by Bethany Smith

SCMOM 2012_Stanford Cardiovascular Institute
Stanford Cardiovascular Institute (CVI) is the nucleus for cardiovascular research at Stanford University. Formed in 2004, the Cardiovascular Institute is home to Stanford #39;s myriad cardiovascular-related adult and pediatric research, clinical, and educational programs, centers and laboratories, as well as over 500 Stanford basic scientists, graduate students, clinician scientists, and other researchers in heart and vessel disease and prevention. Within the area of cardiac regenerative medicine, the Stanford CVI has significant research endeavors involving human pluripotent stem cells for (1) cardiovascular disease modeling, (2) drug screening and discovery, and (3) personalized cell therapy. Recently, Stanford CVI investigators received a $20 million CIRM Disease Team Therapy Award for performing pre-IND work that would enable the first-in-man clinical trial involving injection of human embryonic stem cell-derived cardiomyocytes for patients with heart failure. wulab.stanford.edu Presenter Joseph Wu, Associate Professor, Cardiovascular Medicine, Stanford University School of MedicineFrom:AllianceRegenMedViews:3 0ratingsTime:17:06More inScience Technology

Read more here:
SCMOM 2012_Stanford Cardiovascular Institute - Video

Recommendation and review posted by simmons

What #39;s in Your Genes: Whole Genome Sequencing and its Impact on Personalized Medicine
From:SITN BostonViews:0 1ratingsTime:01:55:39More inScience Technology

Go here to read the rest:
What's in Your Genes: Whole Genome Sequencing and its Impact on Personalized Medicine - Video

Recommendation and review posted by sam

Episode 2. Personalized Medicine
#12298;Unveiling the Secrets of Biotechnology #65306;Volume #8741; #12299; Part 1 #65306;DoReMi -- The Notes of Life Part 2 #65306;Unparalleled Genetic Fortune-Telling Part 3 #65306;Gene Testing Prescribing the Right MedicineFrom:ccleestagViews:0 0ratingsTime:22:43More inScience Technology

View original post here:
Episode 2. Personalized Medicine - Video

Recommendation and review posted by sam

SCMOM 2012_RhinoCyte
RhinoCyte trade;, Inc., is a biopharmaceutical company focused on developing innovative stem cell therapies for neurodegenerative diseases. Founded in 2005, the company has raised $5 million to date to develop this transformational technology to treat Spinal Cord Injury and Parkinson #39;s Disease to extend and enhance the quality of human life. The first RhinoCyte trade; product is for Spinal Cord Injury (SCI). The IND submission for SCI is 4Q12. RhinoCyte trade; is currently raising a $10 Million Series B financing to fund the Spinal Cord Injury Phase I Clinical Trial program and facilitate the clinical status of the Parkinson #39;s disease product. http://www.rhinocyte.com Presenter: Teresa Leezer, COO, RhinoCyteFrom:AllianceRegenMedViews:3 1ratingsTime:10:07More inScience Technology

Originally posted here:
SCMOM 2012_RhinoCyte - Video

Recommendation and review posted by sam

From Heels to Wheels: My fight from paralysis
I #39;m a c-5 spinal cord injury survivor.. I was never supposed to feel or move anything below my chest ever again... this is my journey to defying the odds.From:taccettaableViews:1436 38ratingsTime:08:40More inPeople Blogs

Follow this link:
From Heels to Wheels: My fight from paralysis - Video

Recommendation and review posted by sam

Trey McClendon
Trey McClendon, a young man in Florida, broke his neck during a diving accident in September 12, and is now living with a spinal cord injury. Trey wrote and recorded this song "Press On". You can get your own copy of the song for just a dollar at helptrey.forabuck.com All proceeds go to help Trey and his family.From:AtlantaProjectWalkViews:0 0ratingsTime:05:46More inNonprofits Activism

Read the original:
Trey McClendon - Video

Recommendation and review posted by sam

Friends of Belmiro #39;s
A fundraising event to benefit the Friends of The Path Spinal Cord Injury AssociationFrom:Charlotte WViews:3 0ratingsTime:03:56More inTravel Events

See original here:
Friends of Belmiro's - Video

Recommendation and review posted by sam

SCMOM 2012_Equalix
Eqalix has received exclusive commercial licensing rights from three prominent institutions for several groundbreaking technologies in Regenerative Medicine which have the potential to revolutionize the unmet needs in multiple commercial and therapeutic applications. These technologies introduce the second generation of products into development and address previously unmet medical needs in the Regenerative Medicine space. Using these technologies, Eqalix plans to develop and commercialize (a) plant-protein based nano-fiber scaffold for use in wound healing and aesthetic dermatology; (b) small-diameter hybrid vessels that foster the creation of a functional endothelium (c) 3-Dimensional tissue scaffolds with adjustable properties for organ and tissue replacement and repair. http://www.eqalix.com Presenter: Joseph Connell, CEO, EqalixFrom:AllianceRegenMedViews:0 0ratingsTime:16:47More inScience Technology

View post:
SCMOM 2012_Equalix - Video

Recommendation and review posted by sam

SCMOM 2012_ViaCyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01), with subcutaneous implantation in a retrievable and immune-isolating encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin in a regulated manner to control blood glucose levels. ViaCyte #39;s goal is a product that can free Type 1 and 2 diabetic patients from long-term insulin dependence. ViaCyte has received substantial financial support from both CIRM and JDRF. http://www.viacyte.com Presenter: Paul Laikind, President and CEO, ViaCyteFrom:AllianceRegenMedViews:5 1ratingsTime:16:42More inScience Technology

Visit link:
SCMOM 2012_ViaCyte - Video

Recommendation and review posted by sam

SCMOM 2012_MaxCyte
MaxCyte is the leader in scalable and clinical cell transfection, bringing to market its patented flow electroporation technology. MaxCyte is applying its significant capabilities in the discovery, development, and manufacturing of virtually all classes of innovative therapeutics targeting a broad range of diseases. MaxCyte #39;s customers and partners utilize its technologies in the development and commercialization of cell-based therapies in regenerative medicine and active cell immunotherapies and in the discovery and development of protein drugs, monoclonal antibodies, vaccines, and small molecule drugs. This clinical-grade cell loading technology is fully developed, well validated and has received MF designation with CBER at US FDA. http://www.maxcyte.com Presenter: Douglas Doerfler, President and CEO, MaxCyteFrom:AllianceRegenMedViews:2 1ratingsTime:13:14More inScience Technology

Read more:
SCMOM 2012_MaxCyte - Video

Recommendation and review posted by sam